Cargando…

Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody

Hepatocellular carcinoma (HCC) is an aggressive liver tumor that occurs due to chronic liver disease, and it has a high mortality rate and limited treatment options. Immune checkpoint inhibitors have been successfully introduced and used in cancer therapy, among which inhibitors of programmed death...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Gang, Zhou, Wenxuan, Li, Xiaoli, Guo, Lijie, He, Tingting, Zhao, Juan, Gong, Liansheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422947/ https://www.ncbi.nlm.nih.gov/pubmed/34504494 http://dx.doi.org/10.3389/fimmu.2021.712351

Ejemplares similares

Complete response to an anti-programmed cell death 1 antibody following a combination therapy of an anti-programmed cell death ligand 1 antibody and a tyrosine kinase inhibitor for metastatic renal cell carcinoma
por: Kurokawa, Masayuki, et al.
Publicado: (2023)

Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
por: Jaafar, Jaafar, et al.
Publicado: (2018)

Case of fulminant type 1 diabetes induced by the anti‐programmed death‐ligand 1 antibody, avelumab
por: Shibayama, Yui, et al.
Publicado: (2019)

Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody
por: Nagaya, Tadanobu, et al.
Publicado: (2016)

Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma
por: Nie, Run-Cong, et al.
Publicado: (2020)

Clinical Response to Anti–Programmed Death 1 After Response and Subsequent Progression on Anti–Programmed Death Ligand 1 Therapy
por: Castellanos, Emily H., et al.
Publicado: (2017)

Re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients previously treated with anti-programmed death-1 and/or anti-programmed death ligand-1 antibodies
por: Imakita, Takuma, et al.
Publicado: (2023)

Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma
por: Rajan, Arun, et al.
Publicado: (2019)

Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody
por: Zhang, Lin, et al.
Publicado: (2022)

Focused Ultrasound-Mediated Delivery of Anti-Programmed Cell Death-Ligand 1 Antibody to the Brain of a Porcine Model
por: Fadera, Siaka, et al.
Publicado: (2023)

Anti-tumor immunity enhancement by photodynamic therapy with talaporfin sodium and anti-programmed death 1 antibody
por: Sasaki, Makiko, et al.
Publicado: (2023)

Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature
por: TSIOGKA, Aikaterini, et al.
Publicado: (2021)

A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies
por: Huang, Anfei, et al.
Publicado: (2017)

Autoimmune fasciitis triggered by the anti-programmed cell death-1 monoclonal antibody nivolumab
por: Parker, Matthew JS, et al.
Publicado: (2018)

Bioengineering and computational analysis of programmed cell death ligand-1 monoclonal antibody
por: Kalim, Muhammad, et al.
Publicado: (2022)

Development of polyclonal heavy chain antibodies targeting programmed death ligand-1
por: Oghalaie, Akbar, et al.
Publicado: (2023)

Intrinsic insulin secretion capacity might be preserved by discontinuing anti‐programmed cell death protein 1 antibody treatment in ‘anti‐programmed cell death protein 1 antibody‐induced’ fulminant type 1 diabetes
por: Sakai, Gota, et al.
Publicado: (2018)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Clinical Perspectives to Overcome Acquired Resistance to Anti–Programmed Death-1 and Anti–Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
por: Lee, Yong Jun, et al.
Publicado: (2021)

Targeting programmed death ligand 2/repulsive guidance molecule b pathway: a novel strategy to subdue tumor immunotherapy resistance to anti‐programmed death 1/programmed death ligand 1
por: Xiang, Yuancai, et al.
Publicado: (2023)

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
por: Rosenberg, Jonathan E., et al.
Publicado: (2019)

Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti–programed death-ligand 1 (Avelumab)
por: Gill, Amanda L., et al.
Publicado: (2016)

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
por: Homet Moreno, B, et al.
Publicado: (2015)

Focused Ultrasound-Enhanced Delivery of Intranasally Administered Anti-Programmed Cell Death-Ligand 1 Antibody to an Intracranial Murine Glioma Model
por: Ye, Dezhuang, et al.
Publicado: (2021)

Anti-tumor effects of anti-programmed cell death-1 antibody treatment are attenuated in streptozotocin-induced diabetic mice
por: Ito, Masaaki, et al.
Publicado: (2023)

Anti-programmed cell death-1 (PD-1) monoclonal antibodies involve reversible cranial dura matter
por: Kataoka, Hiroshi, et al.
Publicado: (2021)

Brachial Plexus Neuritis Associated With Anti–Programmed Cell Death-1 Antibodies: Report of 2 Cases
por: Alhammad, Reem M., et al.
Publicado: (2017)

Biomarkers for Predicting Anti-Programmed Cell Death-1 Antibody Treatment Effects in Head and Neck Cancer
por: Tanaka, Katsunori, et al.
Publicado: (2023)

Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas
por: Yang, Min-Wei, et al.
Publicado: (2019)

Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment
por: Macek Jilkova, Zuzana, et al.
Publicado: (2019)

Effectiveness and safety of lenvatinib plus anti‐programmed death‐1 antibodies in patients with hepatocellular carcinoma: A real‐world cohort study
por: Xu, Ming‐Hao, et al.
Publicado: (2023)

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2021)

Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management
por: Shen, John, et al.
Publicado: (2018)

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
por: Banerjee, Debasree, et al.
Publicado: (2018)

Inhibition of Programmed Death Receptor-1/Programmed Death Ligand-1 Interactions by Ginsenoside Metabolites
por: Yim, Nam-Hui, et al.
Publicado: (2020)

Expression of Programmed Death-Ligand 1 and Programmed Death-1 in Patients with Extramammary Paget's Disease
por: Goto, Hiroyuki, et al.
Publicado: (2021)

Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer
por: Kim, Ji-Hyun, et al.
Publicado: (2019)

Roles of programmed death protein 1/programmed death-ligand 1 in secondary brain injury after intracerebral hemorrhage in rats: selective modulation of microglia polarization to anti-inflammatory phenotype
por: Wu, Jie, et al.
Publicado: (2017)

Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers
por: Mouri, Atsuto, et al.
Publicado: (2021)

Case Report: Durable complete response of metastatic hepatocellular carcinoma with asymptomatic hyperamylasemia to combined immunotherapy of anti-cytotoxic T lymphocyte-associated antigen 4 plus anti-programmed cell death-1 antibodies
por: Gao, Han, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6rdu6lf775nsds27hunbn28stu